Tests blood cleaning treatment for severe ischemic stroke
Tests hemoadsorption, a blood-cleaning procedure, in adults with severe ischemic stroke.
Plain-language title generated from the registry record
Registry title: Hemoadsorption for Severe Ischemic Stroke
Key facts
- Where
- Wuhu, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07127484, who can take part
Where in China
- The First Affiliated Hospital of Wannan Medical University (Yijishan Hospital)Wuhu, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- First Affiliated Hospital of Wannan Medical College
- Trial code
- NCT07127484
- Record updated
- 4 September 2026
- Original description
This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic strokeRead full original descriptionShow less
Efficacy and Safety of Hemoadsorption for Severe Ischemic Stroke
This is a multicenter, randomized-controlled, open-label, blinded endpoint clinical trial that aims to evaluate the efficacy and safety of hemoadsorption for severe ischemic stroke
Inclusion: 1.18 years ≤ age < 80 years; 2.Pre-stroke mRS score ≤ 1; 3.Anterior circulation cerebral infarction within 48 hours of onset, meeting at least one of the following:; 15≤ NIHSS score ≤32; 3<GCS score ≤12; CT hypodensity area >1/2 of the MCA territory; 4.hs-CRP ≥2 mg/L at randomization; 5.If reperfusion therapy is performed, no improvement in NIHSS score (still ≤32) post-treatment; 6.Signed informed consent obtained.
Exclusion: Hemorrhagic transformation of PH2 type prior to randomization; Participation in another drug or device clinical trial within the past 30 days or ongoing enrollment in such trials; Absolute contraindications to hemoadsorption therapy; Hemodynamic instability refractory to medical correction (systolic blood pressure <70 mmHg or diastolic blood pressure <50 mmHg) or decompensated heart failure (NYHA Class III or IV); Deep vein thrombosis (DVT) of the lower extremities before randomization; Life expectancy <90 days due to malignancy; Severe hepatic impairment (defined as ALT >2 times the upper limit of normal or AST >2 times the upper limit of normal) and renal impairment (defined as serum creatinine >1.5 times the upper limit of normal or estimated glomerular filtration rate [eGFR] <50 mL/min); Coagulopathy or thrombocytopenia (platelet count <100×10⁹/L); Brain herniation or decompressive craniectomy performed before randomization; Women of childbearing potential with a negative pregnancy test who refuse to use effective contraception, or pregnant/lactating women.